Dreman Value Management’s AstraZeneca AZN Stock Holding History

Dreman Value Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$6K	Hold	90	–	–	﹤0.01%	421
2017 Q4	$6K	Hold	90	–	–	﹤0.01%	414
2017 Q3	$6K	Hold	90	–	–	﹤0.01%	391
2017 Q2	$6K	Buy	+90	New	+$5.88K	﹤0.01%	384
2017 Q1	–	Sell	-90	Closed	-$5K	–	252
2016 Q4	$5K	Sell	90 -571	-86%	-$32.4K	﹤0.01%	375
2016 Q3	$43K	Hold	661	–	–	0.03%	249
2016 Q2	$40K	Buy	+661	New	+$38.4K	0.02%	236
2015 Q2	–	Sell	-27,489	Closed	-$1.88M	–	429
2015 Q1	$1.88M	Sell	27,489 -1,275	-4%	-$88.6K	0.16%	188
2014 Q4	$2.02M	Sell	28,764 -88,239	-75%	-$6.32M	0.17%	194
2014 Q3	$8.36M	Sell	117,003 -829	-0.7%	-$60.7K	0.68%	38
2014 Q2	$8.76M	Sell	117,832 -17,607	-13%	-$1.27M	0.66%	40
2014 Q1	$8.79M	Buy	135,439 +28,464	+27%	+$1.84M	0.68%	44
2013 Q4	$9.63M	Sell	106,975 -72,286	-40%	-$3.93M	0.73%	22
2013 Q3	$9.31M	Buy	+179,261	New	+$9M	0.84%	10

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dreman Value Management's AZN Position: Q1 2018 in Review

Dreman Value Management held its AstraZeneca (AZN) position steady in Q1 2018 at 90 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

Dreman Value Management first reported a position in AZN in Q3 2013 and has held it in 14 quarters since. The position peaked at $9.63M in Q4 2013. 518 funds tracked by Wall St. Rank hold AZN as of Q1 2018.

Dreman Value Management held 90 shares of AstraZeneca worth $6K as of Q1 2018.
Dreman Value Management left its AstraZeneca share count unchanged in Q1 2018.
AstraZeneca made up ﹤0.01% of Dreman Value Management's portfolio in Q1 2018, its #421 holding.
Dreman Value Management first reported a position in AstraZeneca in Q3 2013 and has held it in 14 quarters since.
Dreman Value Management's AstraZeneca position peaked at $9.63M in Q4 2013.
518 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2018.

Based on Dreman Value Management's 13F filing for Q1 2018, filed 2 May 2018.